Compare Neurocrine Biosciences Inc (NBIX) vs Invesco WilderHill Clean Energy ETF (PBW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Invesco WilderHill Clean Energy ETF — how do they compare? Neurocrine Biosciences Inc trades at $155 (market cap $15.77B), while Invesco WilderHill Clean Energy ETF trades at $31.54. The key difference: Neurocrine Biosciences Inc is trading nearer its 52-week high, Invesco WilderHill Clean Energy ETF nearer its low. Which is the better fit depends on your goals.
| NBIX | PBW | |
|---|---|---|
Market Cap | $15.77B | — |
Sector | Health | Sector/Thematic |
52-Week High | $185.50 | $46.99 |
52-Week Low | $123.10 | $24.75 |
Enterprise Value | $15.78B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
PBW (Invesco WilderHill Clean Energy ETF) trades at $32.38, up 1.86% today, but technical indicators show a bearish trend with moving averages signaling selling pressure. The ETF's unique selection criteria focusing on ecological factors over financial metrics creates an undiversified portfolio that has underperformed broader markets. Recent market volatility from geopolitical tensions and tech sector sell-offs has impacted clean energy ETFs despite long-term growth catalysts.
The clean energy sector faces near-term headwinds from market volatility, though long-term prospects remain supported by global energy security concerns and substantial international investment. PBW's performance remains tied to clean energy adoption trends and policy developments, with current technical weakness suggesting cautious near-term positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Invesco WilderHill Clean Energy ETF
PBW is an equal-weighted ETF that invests in U.S. companies leading the clean energy transition. It focuses on renewable energy, power conservation, and sustainable technologies like solar, wind, and energy storage.
Read more on PBW →
